By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Supernus Pharmaceuticals 

1550 East Gude Drive

Rockville  Maryland  20850  U.S.A.
Phone: 301-838-2501 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Supernus
Symbol: SUPN


Company News
Supernus (SUPN) Wins Appeal Case On Oxtellar XR 12/13/2016 8:12:46 AM
Supernus (SUPN) Receives Nasdaq Non-Compliance Notice 11/18/2016 7:29:24 AM
Supernus (SUPN) Provides Business Update 11/14/2016 7:49:49 AM
Investors Relieved as Supernus (SUPN) ADHD Drug Meets Goals in Phase IIb Study 10/11/2016 7:08:32 AM
Supernus Pharmaceuticals (SUPN) Receives FDA Tentative Approval For Expanded Label Of Trokendi XR To Include Migraine Prophylaxis In Adults 8/22/2016 7:10:21 AM
Supernus Pharmaceuticals (SUPN) Announces Second Quarter 2016 Financial Results 8/3/2016 10:55:06 AM
Supernus Pharmaceuticals (SUPN) To Host Second Quarter 2016 Earnings Conference Call 7/21/2016 8:12:58 AM
Supernus Pharmaceuticals (SUPN) Founder And CEO Jack Khattar Joins scPharmaceuticals Board Of Directors 7/12/2016 7:55:22 AM
Supernus Pharmaceuticals (SUPN) Selects DSG, Inc. For EDC And IWRS In Phase III Clinical Studies On Impulsive Aggression In Pediatric Patients Treated For Attention Deficit/Hyperactivity Disorder (ADHD) 4/1/2016 10:32:01 AM
Supernus Pharmaceuticals (SUPN) Announces Record Fourth Quarter And Full Year 2015 Financial Results 3/3/2016 7:47:28 AM